You have 9 free searches left this month | for more free features.

Relapsed, Refractory

Showing 1 - 25 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Relapsed/Refractory Waldenstrom Macroglobulinemia, Relapsed/Refractory Richter Transformation, Relapsed/Refractory Burkitt

Not yet recruiting
  • Relapsed/Refractory Waldenstrom Macroglobulinemia
  • +3 more
  • Brexucabtagene Autoleucel
  • +2 more
  • (no location specified)
Sep 8, 2022

Relapsed/Refractory Higher-Risk Myelodysplastic Syndrome, Relapsed/Refractory Acute Myeloid Leukemia Trial (Magrolimab)

Available
  • Relapsed/Refractory Higher-Risk Myelodysplastic Syndrome
  • Relapsed/Refractory Acute Myeloid Leukemia
  • Magrolimab
  • (no location specified)
Jan 18, 2023

Relapsed/Refractory Multiple Myeloma, Amyloid Light-chain Amyloidosis Trial (SAR445514)

Not yet recruiting
  • Relapsed/Refractory Multiple Myeloma
  • Amyloid Light-chain Amyloidosis
  • (no location specified)
Apr 20, 2023

Relapsed/Refractory B-cell Malignancies Trial (AC676)

Not yet recruiting
  • Relapsed/Refractory B-cell Malignancies
  • (no location specified)
Mar 27, 2023

Relapsed/Refractory Multiple Myeloma Trial in Benowa (ISB 2001)

Not yet recruiting
  • Relapsed/Refractory Multiple Myeloma
  • ISB 2001
  • Benowa, Queensland, Australia
    Pindara Private Hospital
May 18, 2023

Relapsed/Refractory Diffuse Large B Cell Lymphoma Trial in Seoul (Glofitamab, Poseltinib, Lenalidomide)

Recruiting
  • Relapsed/Refractory Diffuse Large B Cell Lymphoma
  • Glofitamab, Poseltinib, Lenalidomide
  • Seoul, Korea, Republic of
    Seoul National University Hospital
Nov 28, 2022

Relapsed/Refractory Immune Thrombocytopenia Trial in Seoul (Bortezomib)

Not yet recruiting
  • Relapsed/Refractory Immune Thrombocytopenia
  • Seoul, Korea, Republic of
  • +1 more
Oct 30, 2022

Relapsed/Refractory Follicular Lymphoma With EZH2 Trial in Shanghai (Tazemetostat)

Not yet recruiting
  • Relapsed/Refractory Follicular Lymphoma With EZH2
  • Shanghai, Shanghai, China
    Shanghai Cancer Center
Jul 20, 2022

Relapsed/Refractory Acute Myeloid Leukemia Trial in Hangzhou (B7-H3 target, CAR gene modified gdT cell injection)

Recruiting
  • Relapsed/Refractory Acute Myeloid Leukemia
  • B7-H3 target, CAR gene modified gdT cell injection
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital´╝î Zhejiang University School of Med
Feb 15, 2023

Relapsed/Refractory AML Trial in Suzhou (Selinexor, Homoharringtonine, Cytarabine)

Not yet recruiting
  • Relapsed/Refractory AML
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Mar 28, 2023

Relapsed/ Refractory Multiple Myeloma Trial (GC012F)

Not yet recruiting
  • Relapsed/ Refractory Multiple Myeloma
  • GC012F
  • (no location specified)
Apr 28, 2023

Relapsed/Refractory Acute Myeloid Leukemia Trial in Hefei (gdT cell injection targeting B7-H3 chimeric antigen receptor)

Recruiting
  • Relapsed/Refractory Acute Myeloid Leukemia
  • gdT cell injection targeting B7-H3 chimeric antigen receptor
  • Hefei, Anhui, China
    PersonGen Anke Cellular Therapeutice Co., Ltd.
Jan 31, 2023

Relapsed/Refractory, Systemic Lupus Erythematosus (SLE) Trial in Zhongshan (BCMA-CD19 cCAR T cells)

Recruiting
  • Relapsed/Refractory, Systemic Lupus Erythematosus (SLE)
  • BCMA-CD19 cCAR T cells
  • Zhongshan, Guangdong, China
    Zhongshan People's Hospital
Jul 23, 2022

Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma Trial in Beijing (JS203 for Injection)

Not yet recruiting
  • Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
  • JS203 for Injection
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Nov 11, 2022

Relapsed/Refractory Multiple Myeloma Trial in Suzhou (Mitoxantrone HCl liposome/Dexamethasone/daratumumab)

Recruiting
  • Relapsed/Refractory Multiple Myeloma
  • Mitoxantrone hydrochloride liposome/Dexamethasone/daratumumab
  • Suzhou, Jiangsu, China
    Second Affiliated Hospital of Soochow University
May 4, 2023

Relapsed/Refractory Large Granular T Lymphocytic Leukemia Trial in Zhoukou, Tianjin (Linperlisib)

Not yet recruiting
  • Relapsed/Refractory Large Granular T Lymphocytic Leukemia
  • Zhoukou, Henan, China
  • +1 more
Dec 22, 2022

Relapsed/Refractory Acute Myeloid Leukemia Trial (LILRB4 STAR-T cells)

Not yet recruiting
  • Relapsed/Refractory Acute Myeloid Leukemia
  • LILRB4 STAR-T cells
  • (no location specified)
Sep 16, 2022

Relapsed/Refractory Lymphoma Trial in Shanghai (tazemetostat, HMPL-689)

Not yet recruiting
  • Relapsed/Refractory Lymphoma
  • Shanghai, China
    Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Feb 2, 2023

B7-H3-positive Relapsed/ Refractory Neuroblastoma Trial in Tianjin (T cell injection targeting FLT3 chimeric antigen receptor)

Not yet recruiting
  • B7-H3-positive Relapsed/ Refractory Neuroblastoma
  • T cell injection targeting FLT3 chimeric antigen receptor
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute and Hospital
Nov 1, 2022

Relapsed/Refractory Multiple Myeloma, Relapsed/Refractory DLBCL Trial in United States (EZM0414)

Recruiting
  • Relapsed/Refractory Multiple Myeloma
  • Relapsed/Refractory Diffuse Large B-Cell Lymphoma
  • Chevy Chase, Maryland
  • +10 more
Jan 12, 2023

Mantle-cell Lymphoma Trial (Polatuzumab, bendamustin und rituximab)

Not yet recruiting
  • Mantle-cell Lymphoma
  • Polatuzumab, bendamustin und rituximab
  • (no location specified)
May 11, 2023

Relapsed/Refractory Multiple Myeloma Trial in Xi'an (LUCAR-B68 cells product)

Not yet recruiting
  • Relapsed/Refractory Multiple Myeloma
  • LUCAR-B68 cells product
  • Xi'an, Shaanxi, China
    Second Affiliated Hospital of Xi'an Jiaotong University
Aug 10, 2022

Refractory CNS Lymphoma, Relapsed Primary CNS Lymphoma, Primary CNS Lymphoma Trial in Hangzhou (Nivolumab)

Active, not recruiting
  • Refractory Central Nervous System Lymphoma
  • +2 more
  • Hangzhou, Zhejiang, China
    Jianmin Zhang
Jul 3, 2022

Relapsed Multiple Myeloma, Refractory Multiple Myeloma Trial (Rapid Infusion Isatuximab)

Withdrawn
  • Relapsed Multiple Myeloma
  • Refractory Multiple Myeloma
  • Rapid Infusion Isatuximab
  • (no location specified)
Jul 3, 2022

Relapsed/Refractory Multiple Myeloma Trial in Beijing, Hangzhou, Shanghai (LCAR-BCDR cells product)

Recruiting
  • Relapsed/Refractory Multiple Myeloma
  • LCAR-BCDR cells product
  • Beijing, Beijing, China
  • +3 more
Dec 15, 2022